Implementing alpelisib with fulvestrant in metastatic breast cancer treatment: safety profile, findings from real-world clinical data

Breast cancer is the most common cancer diagnosed among women in 2021in Croatia, according to the last published data by the Croatian National Cancer Registry. For hormonally dependent – HER2 negative metastatic breast cancer (HR+HER2– mBC) patients with PIK3CA mutations, a PIK3CA inhibitor alpelisi...

Full description

Bibliographic Details

Published in:	Libri Oncologici
Main Authors:	Petra Jakšić, Petra Sertić, Mihaela Trajbar, Ljubica Vazdar, Robert Šeparović, Ana Tečić-Vuger
Format:	Article
Language:	English
Published:	University Hospital for Tumors 2024-01-01
Subjects:	alpelisib breast cancer metastatic disease safety
Online Access:	https://hrcak.srce.hr/file/474887